(Reuters) -Shares in European vaccine makers fell on Friday after U.S. President-elect Donald Trump picked Robert F. Kennedy ...
A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...
The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...
In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...
HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...
CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...
Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out drugs are emerging.
INDIANAPOLIS (AP) — Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations. The drugmaker ...
The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr.
Boston Pharmaceuticals has linked its metabolic dysfunction-associated steatohepatitis (MASH) prospect to improved outcomes ...
Hosted on MSN2d
Could weight loss drugs fix UK’s unemployment problem?The United Kingdom will study whether the use of weight loss drugs could get people back to work. UK Health Minister Wes ...
Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback